Quantisnow Logo
Dashboard

SEC Form SC 13G/A filed

$JAZZ
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $JAZZ alert in real time by email
SC 13G/A 1 jazz-13g_20201231.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY ---------------------------------------------------------------------------- (Name of Issuer) Ordinary shares, nominal value $0.0001 per share ---------------------------------------------------------------------------- (Title of Class of Securities) G50871105 ---------------------------------------------------------------------------- (CUSIP Number) December 31, 2020 ---------------------------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [_] Rule 13d-1(c) [_] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). ============================================================================= ----------------------------------------------------------------------------- CUSIP NO. G50871105 13G Page 2 of 8 Pages ----------------------------------------------------------------------------- (1) NAMES OF REPORTING PERSONS. I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only). Renaissance Technologies LLC 26-0385758 ----------------------------------------------------------------------------- (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS): (a) [_] (b) [_] ----------------------------------------------------------------------------- (3) SEC USE ONLY ----------------------------------------------------------------------------- (4) CITIZENSHIP OR PLACE OF ORGANIZATION Delaware ----------------------------------------------------------------------------- (5) SOLE VOTING POWER NUMBER OF SHARES 3,099,050 BENEFICIALLY OWNED _____________________________ BY EACH REPORTING PERSON WITH: (6) SHARED VOTING POWER 0 _____________________________ (7) SOLE DISPOSITIVE POWER 3,099,050 _____________________________ (8) SHARED DISPOSITIVE POWER 0 ______________________________ (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,099,050 ------------------------------------------------------------------------------ (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_] ------------------------------------------------------------------------------ (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.56 % ------------------------------------------------------------------------------ (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IA Page 2 of 8 pages ============================================================================= Page 3 of 8 pages ----------------------------------------------------------------------------- CUSIP NO. G50871105 13G Page 3 of 8 Pages ----------------------------------------------------------------------------- (1) NAMES OF REPORTING PERSONS. I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY). RENAISSANCE TECHNOLOGIES HOLDINGS CORPORATION 13-3127734 ----------------------------------------------------------------------------- (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) [_] (b) [_] ----------------------------------------------------------------------------- (3) SEC USE ONLY ----------------------------------------------------------------------------- (4) CITIZENSHIP OR PLACE OF ORGANIZATION Delaware ----------------------------------------------------------------------------- (5) SOLE VOTING POWER NUMBER OF SHARES 3,099,050 BENEFICIALLY OWNED _____________________________ BY EACH REPORTING PERSON WITH: (6) SHARED VOTING POWER 0 _____________________________ (7) SOLE DISPOSITIVE POWER 3,099,050 _____________________________ (8) SHARED DISPOSITIVE POWER 0 _____________________________ (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,099,050 ----------------------------------------------------------------------------- (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_] ----------------------------------------------------------------------------- (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.56 % ----------------------------------------------------------------------------- (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) HC Page 3 of 8 pages ============================================================================= ----------------------------------------------------------------------------- CUSIP NO. G50871105 13G Page 4 of 8 Pages ----------------------------------------------------------------------------- Item 1. (a) Name of Issuer JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY (b) Address of Issuer's Principal Executive Offices. Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland D04 E5W7 Item 2. (a) Name of Person Filing: This Schedule 13G is being filed by Renaissance Technologies LLC ("RTC") and Renaissance Technologies Holdings Corporation ("RTHC"). (b) Address of Principal Business Office or, if none, Residence. The principal business address of the reporting persons is: 800 Third Avenue New York, New York 10022 (c) Citizenship. RTC is a Delaware limited liability company, and RTHC is a Delaware corporation. (d) Title of Class of Securities. Ordinary shares, nominal value $0.0001 per share (e) CUSIP Number. G50871105 Page 4 of 8 pages ============================================================================= Item 3. If this statement is filed pursuant to Rule 13d-1(b) or 13-d-2(b) or (c),check whether the person filing is a: (a) [_] Broker or dealer registered under section 15 of the Act. (b) [_] Bank as defined in section 3(a)(6) of the Act. (c) [_] Insurance Company as defined in section 3(a)(19) of the Act. (d) [_] Investment Company registered under section 8 of the Investment Company Act. (e) [x] Investment Adviser in accordance with Sec.240.13d-1(b)(1)(ii)(E). (f) [_] Employee Benefit Plan or Endowment Fund in accordance with Sec. 240.13d-1(b)(1)(ii)(F). (g) [_] Parent holding company, in accordance with Sec.240.13d-1(b)(1)(ii)(G). (h) [_] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act. (i) [_] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940. (j) [_] Group, in accordance with Sec.240.13d-1(b)(1)(ii)(J). Item 4. Ownership. (a) Amount beneficially owned. RTC: 3,099,050 shares RTHC: 3,099,050 shares, comprising the shares beneficially owned by RTHC, because of RTHC's majority ownership of RTC. (b) Percent of Class. RTC: 5.56 % RTHC: 5.56 % (c) Number of shares as to which the person has: (i) sole power to vote or to direct the vote: RTC: 3,099,050 RTHC: 3,099,050 (ii) Shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: RTC: 3,099,050 RTHC: 3,099,050 (iv) Shared power to dispose or to direct the disposition of: RTC: 0 RTHC: 0 Page 5 of 8 pages ============================================================================= Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [_] Item 6. Ownership of More than Five Percent on Behalf of Another Person. Certain funds and accounts managed by RTC have the right to receive dividends and proceeds from the sale of the securities which are the subject of this report. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company. Not applicable Item 8. Identification and Classification of Members of the Group. Not applicable Item 9. Notice of Dissolution of a Group. Not applicable Page 6 of 8 pages ============================================================================= Item 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: February 11, 2021 Renaissance Technologies LLC By: /s/ James S. Rowen Chief Operating Officer Renaissance Technologies Holdings Corporation By: /s/ James S. Rowen Vice President Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001). Page 7 of 8 Pages ============================================================================== EXHIBIT 99.1 AGREEMENT REGARDING JOINT FILING UNDER RULE 13D-1(K) OF THE EXCHANGE ACT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the undersigned agrees to the filing on behalf of each of a Statement on Schedule 13G, and all amendments thereto, with respect to the Ordinary shares, nominal value $0.0001 per share of JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY. Date: February 11, 2021 Renaissance Technologies LLC By: /s/ James S. Rowen Chief Operating Officer Renaissance Technologies Holdings Corporation By: /s/ James S. Rowen Vice President Page 8 of 8 Pages
Get the next $JAZZ alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$JAZZ

DatePrice TargetRatingAnalyst
3/7/2025$145.00 → $179.00Neutral → Buy
UBS
2/26/2025Overweight → Neutral
Cantor Fitzgerald
2/13/2025$130.00 → $170.00Equal Weight → Overweight
Wells Fargo
12/12/2024$140.00 → $175.00Equal-Weight → Overweight
Morgan Stanley
6/5/2024$169.00Buy
Goldman
1/3/2024$160.00Outperform
Robert W. Baird
11/27/2023$170.00 → $135.00Buy → Neutral
UBS
9/29/2023Mkt Perform
Raymond James
More analyst ratings

$JAZZ
 Press Releases

Fastest customizable press release news feed in the world

See more

  • Jazz Pharmaceuticals to Showcase Research Demonstrating Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Epidiolex® (cannabidiol) at American Academy of Neurology Annual Meeting

    Updated top-line results demonstrate improved outcomes in adults with narcolepsy or idiopathic hypersomnia treated with Xywav as observed in the Phase 4 DUET (Developing Understanding of Hypersomnia by Evaluating Low-Sodium Oxybate Treatment) study Novel analysis of real-world Epidiolex treatment patterns underscore importance of dose optimization for improved patient persistence For U.S. media and investors only DUBLIN, March 19, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that seven abstracts from across its neuroscience portfolio will be featured at the 77th Annual American Academy of Neurology Meeting (AAN) being held April 5-9, 2025, in San Diego. Data pr

    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio

    -Dordaviprone addresses a significant unmet patient need for patients with rare, high-grade brain tumors- -Transaction to add near-term commercial opportunity to Jazz's pipeline- -Transaction represents total cash consideration of approximately $935 million, or $8.55 per share- DUBLIN and DURHAM, N.C., March 05, 2025 (GLOBE NEWSWIRE) -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ("Jazz" or the "Company") and Chimerix (NASDAQ:CMRX) ("Chimerix"), today announced the companies have entered into a definitive agreement for Jazz to acquire Chimerix for $8.55 per share in cash, representing a total consideration of approximately $935 million. The transaction has been approved by both compani

    $CMRX
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance

    – Record total revenues of $4.1 billion in 2024 and $1.1 billion in 4Q24 –– Xywav® and Epidiolex® revenues grew 16% and 15% year-over-year, respectively, in 2024 –– Oncology revenues grew 9% year-over-year in 2024, surpassed $1.1 billion –– Ziihera® approved in 2L HER2+ (IHC3+) BTC; first sales achieved in December 2024 –– 2025 guidance reflects continued top- and bottom-line growth – DUBLIN, Feb. 25, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced financial results for the full year and fourth quarter of 2024 and provided guidance for 2025. "2024 was another strong year as our proven team delivered significant top- and bottom-line growth along with record total r

    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

$JAZZ
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$JAZZ
 Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$JAZZ
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$JAZZ
 SEC Filings

See more

$JAZZ
 FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

See more

  • August 12, 2021 - FDA Grants First of its Kind Indication for Chronic Sleep Disorder Treatment

    For Immediate Release: August 12, 2021 The U.S. Food and Drug Administration today approved a new indication for Xywav for idiopathic hypersomnia (IH) in adults. IH is an uncommon chronic sleep disorder that causes people to be excessively sleepy during the day even after a good night's sleep. Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution is already approved for the treatment of catapl

    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

$JAZZ
 Leadership Updates

Live Leadership Updates

See more

  • Jazz Pharmaceuticals Announces CEO Succession Plan

    Bruce Cozadd, Co-Founder, Chairperson and CEO, Plans to Retire as CEO Upon Appointment of Successor by the End of 2025; Will Continue as Chair of the Board Mr. Cozadd Has Led Growth of Company from Founding to $4 Billion+ in 2024 Expected Total Revenue Board Will Lead Comprehensive Internal and External Search for New CEO; Intended to be Completed in 2025 DUBLIN, Dec. 16, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that Bruce Cozadd, Co-Founder, Chairperson and Chief Executive Officer (CEO), has informed the Board of Directors of his intent to retire from his role as CEO upon appointment of the Company's next leader, expected by the end of 2025. The Board wil

    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Jazz Pharmaceuticals Shareholders Elect Laura Hamill to the Company's Board of Directors at Annual General Meeting

    Ms. Hamill brings extensive experience and proven leadership focused on commercial growth and shareholder value DUBLIN, July 25, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced the election of a new independent director, Laura Hamill, to its Board of Directors. Ms. Hamill, a 35-year veteran of the pharmaceutical industry brings broad executive leadership and global commercial operations expertise to the company's Board. Ms. Hamill's election follows the appointment of Patrick Kennedy earlier this year and reflects Jazz's continued focus on Board renewal. At the Annual General meeting held today, shareholders not only elected Ms. Hamill and Mr. Kennedy but also re-

    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • NodThera Announces Appointment of Daniel Swisher as Chief Executive Officer

    NodThera INC ("NodThera" or the "Company") NodThera Announces Appointment of Daniel Swisher as Chief Executive Officer Dan joins NodThera with over 30 years of pharmaceutical industry leadership experience, including as President and COO of Jazz Pharmaceuticals and CEO of Sunesis PharmaceuticalsInterim CEO Alan Watt becomes President and CSO including leadership of R&D to further build out NodThera's pioneering work in CNS modulation of chronic inflammatory diseases BOSTON, MA, May 28, 2024 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, today announces the a

    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

$JAZZ
 Financials

Live finance-specific insights

See more

  • Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance

    – Record total revenues of $4.1 billion in 2024 and $1.1 billion in 4Q24 –– Xywav® and Epidiolex® revenues grew 16% and 15% year-over-year, respectively, in 2024 –– Oncology revenues grew 9% year-over-year in 2024, surpassed $1.1 billion –– Ziihera® approved in 2L HER2+ (IHC3+) BTC; first sales achieved in December 2024 –– 2025 guidance reflects continued top- and bottom-line growth – DUBLIN, Feb. 25, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced financial results for the full year and fourth quarter of 2024 and provided guidance for 2025. "2024 was another strong year as our proven team delivered significant top- and bottom-line growth along with record total r

    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Jazz Pharmaceuticals to Report 2024 Full Year and Fourth Quarter Financial Results on February 25, 2025

    DUBLIN, Feb. 11, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that it will report its 2024 full year and fourth quarter financial results on Tuesday, February 25, 2025, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. GMT to discuss 2024 full year and fourth quarter financial results and provide a business and financial update.   Audio webcast/conference call:U.S. Dial-In Number: +1 800 715 9871Ireland Dial-In Number: +353 1800 943 926Additional global dial-in numbers are available here.Passcode: 5080203 Interested parties may access the live audio webcast via the Investors section of t

    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Jazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024

    DUBLIN, Dec. 4, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that it will host a webcast on Wednesday, December 11, 2024, at 4:30 p.m. ET / 9:30 p.m. GMT to provide an overview of clinical data, patient need and commercialization strategy for Ziihera® (zanidatamab-hrii), the first chemotherapy-free dual HER2-targeted bispecific antibody indicated for biliary tract cancer (BTC). Ziihera was approved under accelerated approval by the U.S. Food and Drug Administration (FDA) on November 20, 2024, for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) BTC, as detected by an FDA-approved test.1  Jazz senior management w

    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

$JAZZ
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more